Increased susceptibility to lymphokine activated killer (LAK) lysis of relapsing vs. newly diagnosed acute leukemic cells without changes in drug resistance or in the expression of adhesion molecules-Reference-Cited by-同舟云学术

Increased susceptibility to lymphokine activated killer (LAK) lysis of relapsing vs. newly diagnosed acute leukemic cells without changes in drug resistance or in the expression of adhesion molecules

Published:1992-02 Issue:2 Volume:3 Page:155-162
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Arienti F.,Gambacorti-Passerini C.,Borin L.,Rivoltini L.,Orazi A.,Pogliani E.M.,Corneo G.,Parmiani G.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/3/2/155/530885/3-2-155.pdf

Reference28 articles.

1. Expression of multidrug-resistance gene in human cancers;Goldstein;J Natl Cancer Inst,1985

2. Detection of multi-drug-resistance markers, P-glycoprotein and mdrl mRNA, in human leukemia cells;Tsuruo;Jpn J Cancer Res,1987

3. Multidrug resistance in haemopoietic cell lines, myelodysplastic syndromes and acute myeloblastic leukemia;Holmes;Br J Haemat,1989

4. Lysis by activated lymphocytes of melanoma and small lung cancer cells surviving in vitro treatment with Mafosfamide;Gambacorti-Passerini;Cancer Res,1987

5. Differential lysis of melanoma clones by autologous recombinant-interleukin 2 activated lymphocytes;Gambacorti-Passerini;Relationship with spontaneous resistance to doxorubicin. Int J Cancer,1988

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NLRP4 negatively regulates type I interferon response and influences the outcome in anti‐programmed cell death protein (PD)‐1/PD‐ligand 1 therapy;Cancer Science;2022-01-19

2. Anti-tumor effects of CIK combined with oxaliplatin in human oxaliplatin-resistant gastric cancer cells in vivo and in vitro;Journal of Experimental & Clinical Cancer Research;2010-08-30

3. Acute myelogenous leukemia blasts as accessory cells during T lymphocyte activation: possible implications for future therapeutic strategies;Leukemia;1999-08

4. Cytocidal Activity of PBL, LAK, and IDEC-C2B8 and Expression of HLA Class 1, ICAM-1, and CD20 in Vincristine-Resistant Hematologic Cell Lines;Journal of Immunotherapy;1999-05

5. Influence of Malignant Cell Clonogenic Capacities and Position Along the Maturation Pathway on Their Susceptibility to Lymphokine-Activated Killer Cell Cytotoxicity;Leukemia & Lymphoma;1998-01